The impact of antiplatelet and antithrombotic regimen after TAVI: Data from the VIenna CardioThOracic Aortic Valve RegistrY (VICTORY)

• Published in: European journal of clinical investigation 2021-09, Vol.51 (9), p.e13589-e13589
• Main Authors: Mach, Markus, Watzal, Victoria, Cuhaj, Carina, Hasan, Waseem, Poschner, Thomas, Szalkiewicz, Philipp, Strouhal, Andreas, Adlbrecht, Christopher, Delle-Karth, Georg, Grabenwöger, Martin, Winkler, Bernhard
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Antagonists; Anticoagulants; Anticoagulants - therapeutic use; Aortic Valve Stenosis - surgery; Aspirin - therapeutic use; Austria - epidemiology; Clopidogrel - therapeutic use; Consortia; Dual Anti-Platelet Therapy - methods; Factor Xa Inhibitors - therapeutic use; Female; Fibrinolytic Agents - therapeutic use; Hemorrhage - chemically induced; Hemorrhage - epidemiology; Humans; Male; Mortality; Patients; Phylloquinone; Platelet Aggregation Inhibitors - therapeutic use; Postoperative Care - methods; Registries; Survival; Survival Rate; Transcatheter Aortic Valve Replacement; Vitamin K; Vitamin K - antagonists & inhibitors
• ISSN: 0014-2972; 1365-2362
• DOI: 10.1111/eci.13589

We compared the outcomes and adverse events of TAVI patients based on the discharge and long-term antiplatelet or anticoagulant treatment regimens (single antiplatelet [SAPT] vs. dual antiplatelet [DAPT] vs. anticoagulation [OAC] vs. no treatment [NT]). The outcome of 532 consecutive patients treated with TAVI was evaluated. As the main study endpoint, the 1-year all-cause mortality was chosen to compare the different discharge treatment regimens and the 3-year all-cause mortality to compare the different long-term treatment regimens. The secondary endpoints were adverse events as defined by the Valve Academic Research Consortium-II. One-year survival after TAVI was highest amongst patients treated with DAPT compared to SAPT (P